Moreover, patients with a low tumor PD-L2 also had an increased risk for a low 5-year OS (HR 1.69, 95% CI 1.324–2.161, p < 0.001) compared with patients with high tumor PD-L2 expression (Table 5). This evidence concerns the gene PDCD1LG2 and neoplasm.